 InflaRx NV NASDAQ: IFRX has announced topline results from its U.S. Phase 2 IXPLORE study evaluating vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody ANCA-associated vasculitis AAV. The results of the IXPLORE trial show C5a blockade by vilobelimab is safe and well-tolerated when added to standard of care therapy for AAV. 